Researchers Explore New Approach to Multivirus Drug Development

Why It Matters

Broad‑spectrum, host‑targeted antivirals could slash the $2 billion, 8‑12‑year timeline of traditional drug development and bolster global pandemic readiness by offering a single therapeutic against multiple emerging viruses.

Key Takeaways

• Host‑targeted antivirals aim at human enzymes viruses rely on
• RMC‑113 blocked viruses from four families in cell studies
• Dual‑enzyme inhibition may prevent viral resistance development
• Repurposing metformin and statins shows antiviral potential
• Pharma interest growing, but RMC‑113 needs stability improvements

Pulse Analysis

The persistent threat of novel viral outbreaks has exposed the limitations of the conventional, virus‑specific drug pipeline, which averages a decade and billions of dollars per candidate. By shifting focus to host factors that viruses hijack, researchers aim to create a class of antivirals that remain effective across taxonomic boundaries and are inherently less prone to resistance. This paradigm mirrors the broader trend in precision medicine, where targeting host pathways can yield durable therapeutic benefits while sidestepping the rapid mutational arms race that plagues direct‑acting antivirals.

In the latest pre‑clinical breakthrough, Einav’s team reported that RMC‑113 simultaneously inhibits two host enzymes critical for viral entry and replication. The compound demonstrated activity against SARS‑CoV‑2, dengue, Ebola, Marburg and Venezuelan equine encephalitis viruses, representing four separate families. Because the drug targets cellular machinery rather than viral proteins, a virus would need to acquire multiple coordinated mutations to escape, a scenario that is statistically improbable. Moreover, early safety signals suggest that short‑term modulation of these enzymes is tolerable, opening a therapeutic window for acute infections without the chronic toxicity concerns of many direct antivirals.

Industry observers see host‑targeted antivirals as a strategic hedge against future pandemics. The approach could dramatically reduce R&D costs by allowing a single molecule to address multiple indications, thereby expanding market potential and encouraging investment. Additionally, the concept of repurposing well‑characterized drugs such as metformin and statins accelerates the path to clinical trials, leveraging existing safety data. As pharmaceutical firms engage with Einav’s lab, the next milestones will involve optimizing pharmacokinetics, validating efficacy in animal models, and navigating regulatory pathways that currently lack clear precedents for host‑directed infectious disease therapies.